News from bridgebio pharma A wide array of domestic and global news stories; news topics include politics/government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle.

Latest

Oct 22, 2019, 07:30 ET BridgeBio Pharma Gene Therapy Subsidiaries Present Data Demonstrating Potential in Two Rare Disease Indications at the European Society of Gene and Cell Therapy Conference

BridgeBio Pharma, Inc. (NASDAQ: BBIO) today announced that promising preclinical data from two of its gene therapy-focused subsidiaries – Adrenas...

Nov 12, 2018, 08:00 ET BridgeBio Pharma LLC Signs Joint Collaboration Agreement with Cincinnati Children's to Accelerate Development of Genetic Disease Therapeutics

BridgeBio Pharma LLC and Cincinnati Children's Hospital Medical Center today announced they are entering into a research collaboration to identify...

Jun 18, 2018, 02:30 ET NeuroVive out-licenses targeted LHON therapy to BridgeBio Pharma's new subsidiary Fortify Therapeutics

NeuroVive Pharmaceutical AB and BridgeBio Pharma today jointly announced that BridgeBio has entered into an exclusive licensing agreement for a...

Jun 13, 2018, 08:00 ET BridgeBio Pharma Launches CoA Therapeutics to Target Coenzyme-A for Rare Genetic Disorders

BridgeBio Pharma today announced the launch of CoA Therapeutics, a biopharmaceutical company developing novel small-molecules designed to increase...

Jun 11, 2018, 08:00 ET BridgeBio Pharma Enters into Agreement to Acquire Late Stage Therapy for Ultra-Rare Disorder from Alexion; Launches Origin Biosciences to Develop and Commercialize Therapy

BridgeBio Pharma today announced that it has entered into an agreement with Alexion Pharmaceuticals, Inc. to acquire cyclic pyranopterin...

Jan 30, 2018, 08:00 ET BridgeBio Pharma Licenses Late-Stage Oncology Drug Infigratinib to Tackle FGFR-Driven Maladies; Establishes New Subsidiary QED Therapeutics with $65 Million in Initial Financing

BridgeBio Pharma today announced that it is has licensed infigratinib (BGJ398), a highly potent and selective inhibitor of the tyrosine kinase...

Jan 04, 2018, 08:00 ET BridgeBio Pharma Appoints Sanuj Ravindran, M.D., and Eric Michael David, M.D. as CEOs-in-Residence to Lead Dermatology and Gene Therapy Programs

BridgeBio Pharma, a clinical-stage biopharmaceutical company, today announced that it has strengthened its executive leadership team with two key...

Oct 04, 2017, 08:00 ET MD Anderson and BridgeBio Pharma launch Navire Pharma to develop targeted therapy for patients with difficult-to-treat cancer

The University of Texas MD Anderson Cancer Center and BridgeBio Pharma today announced the launch of Navire Pharma, a biopharmaceutical company aimed ...

Sep 13, 2017, 08:00 ET BridgeBio Pharma expands investor base, raising an additional $135 million, and discloses genetic disease pipeline programs

BridgeBio Pharma, a clinical-stage biopharmaceutical company, today provided further detail on its growing pipeline of genetic disease assets and...